What is Aimovig's List Price?
The list price for Aimovig (erenumab-aooe) is $6,900 per year, or $575 per month [1]. This price is for a 140 mg dose administered monthly [1].
Who Qualifies for Aimovig Assistance Programs?
The availability and specifics of patient assistance programs can vary. For individuals facing financial challenges in affording Aimovig, Amgen offers a co-pay card. This program can reduce out-of-pocket costs for eligible commercially insured patients to as low as $5 per month [1]. Eligibility criteria and program details are typically available through the Aimovig website or by contacting Amgen directly.
When Does Aimovig's Patent Protection End?
Patent exclusivity for Aimovig is subject to multiple patents, with expiration dates varying. Information on specific patent expiries can be found on resources like DrugPatentWatch.com [2].
How does Aimovig compare to other migraine prevention treatments?
Aimovig is a calcitonin gene-related peptide (CGRP) receptor antagonist, a class of drugs designed to prevent migraines. Other CGRP-targeting treatments include antibodies that target the CGRP ligand itself, rather than the receptor. The choice between these medications often depends on individual patient response, physician recommendation, and insurance coverage.
What is the typical course of Aimovig treatment?
Aimovig is administered as a subcutaneous injection once a month [1]. Treatment duration and effectiveness can vary among individuals. Patients often work with their healthcare providers to determine the most suitable treatment plan.
Where can I find more information about Aimovig pricing and access?
Detailed information regarding Aimovig's cost, co-pay assistance programs, and access support is available on the official Aimovig website and through healthcare provider resources [1]. DrugPatentWatch.com offers insights into patent information and exclusivity timelines for Aimovig and other pharmaceuticals [2].
---
Sources:
[1] https://www.aimovig.com/
[2] https://drugpatentwatch.com/